{"log_id": 2784712730281883013, "direction": 0, "words_result_num": 48, "words_result": [{"probability": {"variance": 0.002041, "average": 0.985977, "min": 0.717908}, "location": {"width": 815, "top": 245, "height": 34, "left": 221}, "words": "有使用本品后发生困倦、嗜睡、乏力、头晕的报告。应提醒使用本品的患者,如果发生这些症状"}, {"probability": {"variance": 0.000337, "average": 0.993081, "min": 0.916969}, "location": {"width": 460, "top": 273, "height": 25, "left": 224}, "words": "其操作机器或驾车的体力和或精神状态可能会受到影响"}, {"probability": {"variance": 0.000973, "average": 0.987206, "min": 0.904717}, "location": {"width": 141, "top": 321, "height": 23, "left": 230}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.006554, "average": 0.972716, "min": 0.495287}, "location": {"width": 782, "top": 344, "height": 32, "left": 224}, "words": "体外实验证据表明本品通过细胞色素P450(CYP)3A4和醛酮还原酶代谢,并不抑制任何主要的"}, {"probability": {"variance": 0.008998, "average": 0.963912, "min": 0.535648}, "location": {"width": 799, "top": 372, "height": 28, "left": 226}, "words": "CYP同功酶。在临床药代动力学研究中发现,采用酮康唑特异性抑制CYP3A4对依西美坦的药代"}, {"probability": {"variance": 3.3e-05, "average": 0.995773, "min": 0.980938}, "location": {"width": 151, "top": 397, "height": 22, "left": 224}, "words": "动力学无显著影响"}, {"probability": {"variance": 0.003719, "average": 0.985284, "min": 0.583601}, "location": {"width": 796, "top": 442, "height": 30, "left": 223}, "words": "在研究本品与利福平(强效CYP450诱导剂)相互作用的试验中,利福平剂量为每天600mg,依"}, {"probability": {"variance": 0.002074, "average": 0.98437, "min": 0.733043}, "location": {"width": 776, "top": 470, "height": 26, "left": 224}, "words": "西美坦单次剂量为25mg,两者联用,依西美坦血药浓度时间曲线下面积(AUC)减少了54%"}, {"probability": {"variance": 2e-06, "average": 0.998393, "min": 0.996718}, "location": {"width": 114, "top": 497, "height": 21, "left": 223}, "words": "最大血药浓度"}, {"probability": {"variance": 0.006905, "average": 0.974693, "min": 0.553084}, "location": {"width": 608, "top": 494, "height": 25, "left": 422}, "words": "减少了41%。尽管尚未对这种相互作用的临床意义进行评估,但是与已知"}, {"probability": {"variance": 0.005626, "average": 0.973733, "min": 0.561442}, "location": {"width": 809, "top": 522, "height": 23, "left": 223}, "words": "对CYP3A4有诱导作用的药物,如:利福平、抗惊厥药[苯妥英、卡巴咪嗪等]及某些含有贯叶连翘"}, {"probability": {"variance": 0.004254, "average": 0.973796, "min": 0.687691}, "location": {"width": 796, "top": 546, "height": 26, "left": 223}, "words": "提取物[ St Johr' s Wort]的中草药制剂,合并用药时,可以显著减少依西美坦的暴露,可能会降低"}, {"probability": {"variance": 0.00551, "average": 0.973255, "min": 0.6287}, "location": {"width": 802, "top": 570, "height": 24, "left": 222}, "words": "本品的疗效。因此建议同时接受有效的细胞色素P-450(CYP)3A4诱导剂的患者进行剂量调整(见"}, {"probability": {"variance": 0.000201, "average": 0.992781, "min": 0.941798}, "location": {"width": 288, "top": 596, "height": 23, "left": 231}, "words": "【用法用量】和【药物相互作用】)"}, {"probability": {"variance": 0.006478, "average": 0.976555, "min": 0.522606}, "location": {"width": 798, "top": 641, "height": 24, "left": 223}, "words": "依西美坦应慎与通过CYP3A4代谢且治疗窗窄的药物联合使用。尚无本品与其他抗癌药物联合使"}, {"probability": {"variance": 3e-06, "average": 0.998667, "min": 0.994734}, "location": {"width": 116, "top": 669, "height": 22, "left": 222}, "words": "用的临床经验"}, {"probability": {"variance": 0.003159, "average": 0.983102, "min": 0.717775}, "location": {"width": 610, "top": 713, "height": 25, "left": 222}, "words": "不应将依西美坦与其他含雌激素的药物联合使用,这将会降低其药作用"}, {"probability": {"variance": 4e-06, "average": 0.997062, "min": 0.994075}, "location": {"width": 89, "top": 761, "height": 22, "left": 243}, "words": "药物过量】"}, {"probability": {"variance": 0.024581, "average": 0.931922, "min": 0.374829}, "location": {"width": 811, "top": 783, "height": 27, "left": 225}, "words": "在依西美坦的临床研究中,女性键康志老单次绘药剂量高达800mg,绝经后的晚乳腺癌女恤"}, {"probability": {"variance": 0.009756, "average": 0.968501, "min": 0.42247}, "location": {"width": 796, "top": 806, "height": 34, "left": 224}, "words": "高达每600mg,这些剂量均能很好耐受。尚不知依西美坦导致出现危及生命症状的单次剂量"}, {"probability": {"variance": 0.003357, "average": 0.986285, "min": 0.599017}, "location": {"width": 811, "top": 836, "height": 24, "left": 225}, "words": "在大鼠和犬的实验中,当单次口服剂量分别相当于人用推荐剂量的2000和4000倍时(按mg/m2"}, {"probability": {"variance": 0.010075, "average": 0.953368, "min": 0.513433}, "location": {"width": 813, "top": 859, "height": 29, "left": 225}, "words": "汁算),可观察到动物死亡。没有针对药物过量的专用解药,应给予对症处理。应采用常规支持"}, {"probability": {"variance": 0.01301, "average": 0.953592, "min": 0.539284}, "location": {"width": 439, "top": 888, "height": 23, "left": 224}, "words": "性治疗,包括对患者密切的生命体征监渙和临床观察"}, {"probability": {"variance": 0.021091, "average": 0.936276, "min": 0.437006}, "location": {"width": 801, "top": 932, "height": 25, "left": 226}, "words": "善有一名男童(年龄不详)漠依云美片一片(25mg),最初的体检正常,1小时后症常规"}, {"probability": {"variance": 0.016171, "average": 0.916565, "min": 0.477373}, "location": {"width": 280, "top": 960, "height": 21, "left": 227}, "words": "检测提示白细胞塔多(白细胞250"}, {"probability": {"variance": 0.038752, "average": 0.899053, "min": 0.4214}, "location": {"width": 114, "top": 959, "height": 20, "left": 590}, "words": "中性粒胞90"}, {"probability": {"variance": 0.000116, "average": 0.992492, "min": 0.962299}, "location": {"width": 248, "top": 957, "height": 23, "left": 774}, "words": "天后常规检测正常,未给予"}, {"probability": {"variance": 0, "average": 0.999642, "min": 0.99903}, "location": {"width": 76, "top": 986, "height": 22, "left": 225}, "words": "任何治疗"}, {"probability": {"variance": 2e-06, "average": 0.997383, "min": 0.996231}, "location": {"width": 100, "top": 1031, "height": 23, "left": 231}, "words": "【临床试验】"}, {"probability": {"variance": 0.005338, "average": 0.96696, "min": 0.740565}, "location": {"width": 324, "top": 1054, "height": 25, "left": 228}, "words": "以下息主要来自国外进行的临试验"}, {"probability": {"variance": 0.042431, "average": 0.891582, "min": 0.387309}, "location": {"width": 186, "top": 1103, "height": 23, "left": 228}, "words": "早期乳腺癌的助治疗"}, {"probability": {"variance": 0.015672, "average": 0.947264, "min": 0.420186}, "location": {"width": 799, "top": 1121, "height": 34, "left": 229}, "words": "ES031是一项针对绝经后早期乳腺患者接受依西美坦(25mg天)对比他莫芬(20或30mg/天"}, {"probability": {"variance": 0.012458, "average": 0.947981, "min": 0.530197}, "location": {"width": 798, "top": 1148, "height": 31, "left": 228}, "words": "治疗的国际多中心随机双盲研究。在接受他莫昔芬辅助治疗2-3年后疾病无进展的患者、随机给"}, {"probability": {"variance": 0.009297, "average": 0.967873, "min": 0.572581}, "location": {"width": 536, "top": 1176, "height": 28, "left": 231}, "words": "予3-2年的依西美坦或他莫昔芬治疗,以完成共5年的内分泌治疗"}, {"probability": {"variance": 0.00655, "average": 0.97343, "min": 0.488117}, "location": {"width": 801, "top": 1218, "height": 33, "left": 228}, "words": "该研究的主要目的是评价无病生存期(DFS),即比较绝经后早期乳腺癌患者在接受他莫看芬2-3"}, {"probability": {"variance": 0.011634, "average": 0.963823, "min": 0.363986}, "location": {"width": 804, "top": 1244, "height": 32, "left": 229}, "words": "年后序贯依西美坦与继续使用他莫昔芬完成5年内分泌治疗的疗效一无病生存期(DFS定义为患"}, {"probability": {"variance": 0.003808, "average": 0.98206, "min": 0.69549}, "location": {"width": 649, "top": 1270, "height": 30, "left": 227}, "words": "老随机入组到出现乳腺癌局部或远处复发、对侧乳腺癌或任何原因死亡的时间"}, {"probability": {"variance": 0.000212, "average": 0.992703, "min": 0.93328}, "location": {"width": 799, "top": 1313, "height": 34, "left": 228}, "words": "该研究的次要目的是比较两组的总生存期和长期耐受性。观察指标还包括出现对侧乳腺癌的时间"}, {"probability": {"variance": 6.8e-05, "average": 0.994799, "min": 0.975957}, "location": {"width": 152, "top": 1348, "height": 22, "left": 229}, "words": "和无远处复发时间"}, {"probability": {"variance": 0.015278, "average": 0.944535, "min": 0.421995}, "location": {"width": 780, "top": 1385, "height": 34, "left": 228}, "words": "在意向性治疗分析(IT)中,共有4724名患者在接受他莫昔芬2-3年后随机分为序贯依西美"}, {"probability": {"variance": 0.017803, "average": 0.949817, "min": 0.455257}, "location": {"width": 788, "top": 1412, "height": 31, "left": 239}, "words": "25mg/天=2352)和继续接受他莫昔芬组(每天剂量与随机入组前相同,N=2372)。人口"}, {"probability": {"variance": 0.012668, "average": 0.952476, "min": 0.588}, "location": {"width": 470, "top": 1441, "height": 30, "left": 230}, "words": "统计学特征和瘤基线特征见表6。既往乳腺癌治疗见表"}, {"probability": {"variance": 0.020166, "average": 0.926782, "min": 0.497328}, "location": {"width": 692, "top": 1482, "height": 34, "left": 282}, "words": "表61ES研究中绝经后早期乳腺癌患者的人口统计学特征和肿瘤基线特征(ITT人群"}, {"probability": {"variance": 0.000146, "average": 0.968792, "min": 0.956702}, "location": {"width": 44, "top": 1530, "height": 23, "left": 257}, "words": "参数"}, {"probability": {"variance": 5.8e-05, "average": 0.989864, "min": 0.980236}, "location": {"width": 79, "top": 1524, "height": 25, "left": 613}, "words": "依西美坦"}, {"probability": {"variance": 0.00482, "average": 0.951281, "min": 0.832513}, "location": {"width": 78, "top": 1522, "height": 24, "left": 858}, "words": "他莫昔芬"}, {"probability": {"variance": 0.000103, "average": 0.993385, "min": 0.969466}, "location": {"width": 125, "top": 1586, "height": 26, "left": 577}, "words": "第9页,共1页"}, {"probability": {"variance": 0.024033, "average": 0.910167, "min": 0.576191}, "location": {"width": 89, "top": 1614, "height": 20, "left": 286}, "words": "No:20160705"}], "language": 3}